# Sedative-Anxiolytic Effects on Simulated Driving Performance

> **NCT03297944** · PHASE4 · COMPLETED · sponsor: **Marion Coe** · enrollment: 15 (actual)

## Conditions studied

- Psychomotor Impairment

## Interventions

- **DRUG:** Alprazolam 2mg (2ALP/PLC)
- **DRUG:** Alprazolam 1mg (1ALP/PLC)
- **DRUG:** Alprazolam 0.5mg (0.5ALP/PLC)
- **DRUG:** Zolpidem 10mg (ZOL/PLC)
- **DRUG:** Placebo (PLC/PLC)
- **DRUG:** Alprazolam 1mg (PLC/ALC)

## Key facts

- **NCT ID:** NCT03297944
- **Lead sponsor:** Marion Coe
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-15
- **Primary completion:** 2018-10-25
- **Final completion:** 2018-10-25
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03297944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03297944, "Sedative-Anxiolytic Effects on Simulated Driving Performance". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03297944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*